Reasons for study exit
| All patients N=717 | Subset of patients initiating their first TNFi while in Corrona registry N=301 | |
|---|---|---|
| Censored (still with persistent clinical benefit) | 116 (16.2) | 58 (19.3) |
| CDAI >10 | 302 (42.1) | 135 (44.9) |
| Treatment change at same visit | 133/302 (44.0) | 57/135 (42.2) |
| No treatment change at same visit | 169/302 (56.0) | 78/135 (57.7) |
| Addition of | 0 (0) | 0 (0) |
| MTX only | 48 (6.7) | 23 (7·6) |
| Any non-biological DMARD (excluding MTX) | 76 (10.6) | 28 (9.3) |
| Non-biological DMARD and MTX any DMARD | 124 (17.3) | 51 (16.9) |
| Initiation of any biological | 380 (53.0) | 141 (46.8) |
| Prednisone | ||
| Start | 63 (8.8) | 27 (9.0) |
| Dose increase | 28 (3.9) | 12 (4.0) |
Sums may not add to total N=717 (301) as 406 (57) patients had more than one end of benefit defining event (ex. CDAI >10 and biological start) at same visit.
CDAI, clinical disease activity score; DMARD, disease-modifying antirheumatic drugs; MTX, methotrexate; TNFi, tumour necrosis factor inhibitor.